## NOV 16 1006 TO THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dan L. Eaton et al.	Group Art Unit: 1646			
Serial No.: 10/015,967	Examiner: Dong Jiang			
Filed: December 7, 2001	Attorney Docket No: 22338-501 (P1447R1)			
Confirmation No.: 9428				
Title: Interleukin-8 Homologous Polypeptides and Therapeutic Uses Thereof				

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the duty of disclosure provisions of 37 CFR § 1.56, it is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application.

- 1. Form PTO/SB/08 is enclosed with this Information Disclosure Statement. Additionally, copies of the foreign patent documents and non-patent literature documents are also enclosed. Copies of the U.S. patent documents are not enclosed pursuant to 37 CFR § 1.98(a)(2)(ii) and the U.S. Patent and Trademark Office's Waiver of the Copy Requirement in 37 CFR 1.98 for Cited Pending U.S. Patent Applications, 1287 O.G. 163 (Oct. 19, 2004).
- 2. Applicants direct the Examiner's attention to the commonly owned and pending U.S. patent applications listed below.

Serial No.	U.S Publication No.	11/17/2000 Filing Date <sub>FC:1800</sub>	S SZEWDIE1 00000115 181268 First Inventor	10015967
10/795,503	2006-0210991	03/09/2004	Eaton	
10/795,482	2006-0019307	03/09/2004	Eaton	

Serial No.	U.S Publication No.	Filing Date	First Inventor
10/886,040	2005-0100544	07/08/2004	Eaton
11/407,991	2006-0183169	04/21/2006	Eaton
11/528,596	Not Yet Available	09/28/2006	Eaton

- 3. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith). 37 CFR §§ 1.97(g) and (h).
- 4. Applicant notes that EP 1111046, which is reference number 113 on the attached Form PTO/SB/08, is the European regional phase application of the previously considered international application WO 00/14226, which is reference number 95 on the Form PTO-1449 that was submitted on February 28, 2003 and initialed by the Examiner on March 18, 2004.
- 5. It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO/SB/08, and indicate in the official file wrapper of this patent application that the documents have been considered.
- 6. This Information Disclosure Statement is filed after the mailing of a first Office Action on the merits. The Commissioner is authorized to charge the required fee for this Information Disclosure Statement to Deposit Account No. 18-1260.

Respectfully submitted,

November 16, 2006

Gary L. Veron

Registration No. 39,057

Attorney for Applicant

SIDLEY AUSTIN LLP 1501 K Street, N.W. Washington, D.C. 20005 (202) 736-8000

PTO/SB/08A (07-06) Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE

stitute for form 1449/PTO

TRADE

Sheet 1

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/015,967		
Filing Date	December 7, 2001		
First Named Inventor	Dan L. Eaton		
Art Unit	1646		
Examiner Name	Dong Jiang		
Attorney Docket Number	22338-501 (P1447R1)		

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	108	US- 2006-0210991	09-21-2006	Eaton et al.	
	109	<sup>US-</sup> 2006-0019307	01-26-2006	Eaton et al.	
-	110	<sup>US-</sup> 2005-0100544	05-12-2005	Eaton et al.	
	111	<sup>US-</sup> 2006-0183169	08-17-2006	Eaton et al.	
	112	<sup>US-</sup> 11/528,596	None	Eaton et al.	
		US-			
_		US-			
		US-			

		FOREI	GN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
	113	EP 1111046	06-27-2001	Itoh et al.		
	114	WO 99/60160	11-25-1999	Yang et al.		
·	115	WO 98/33926	08-06-1998	Billing-Medel et al.		
						<u> </u>
	<u> </u>					
					ŀ	·'

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/015,967 Filing Date INFORMATION DISCLOSURE December 7, 2001 STATEMENT BY APPLICANT First Named Inventor Dan L. Eaton Art Unit 1646 (Use as many sheets as necessary) **Examiner Name** Dong Jiang Attorney Docket Number Sheet 22338-501 (P1447R1) 2 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	116	JONES; GenTHREADER: An Efficient and Reliable Protein Fold Recognition Method for Genomic Sequences; J. Mol. Biol. (1999) 287, 797-815	
	117	FAGAN; Nicastrin, a presenilin-interacting protein, contains an aminopeptidase/transferrin receptor superfamily domain; TRENDS in Bioch. Sciences; April 2001; 26(4): 213-14	
	118	PISABARRO et al.; Cutting Edge: Novel Human Dendritic Cell- and Monocyte Attracting Chemokine-Like Protein Identified by Fold Recognition Methods; J. Immun. (2006) 2069-73	

Examiner	Date	ļ
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.